Characteristics and treatment strategies of 66 cases of IA-lymphoid neoplasms after ALL
| Characteristics and treatment strategies . | Value, n (% of cases with available data) . |
|---|---|
| Histopathology | |
| Polymorphic LPD resembling polymorphic PTLD | 24 (36) |
| Monomorphic LPD | |
| B cell – DLBCL | 16 (24) |
| T cell | 2 (3) |
| Lymphomatoid granulomatosis | 15 (22) |
| EBV+ mucocutaneous ulcer | 2 (3) |
| LPD, not further specified | 7 (12) |
| Clonality (data available for 22 cases) | |
| Monoclonal | 17 (83) |
| Polyclonal | 5 (17) |
| Tumor EBV status (data available for 55 cases) | |
| Positive by IHC/ISH | 53 (96) |
| Negative | 2 (4) |
| EBV PCR in peripheral blood (copies per mL) (data available for 24 cases) | |
| Positive | 21 (88) |
| Median (range) | 40750 (17-1 500 000) |
| Negative | 3 (12) |
| Staging (data available for 60 cases) | |
| I | 4 (7) |
| II | 6 (10) |
| III | 38 (63) |
| IV | 12 (20) |
| Lymphoid neoplasm treatment strategies (data available for 58 cases) | |
| No systemic chemotherapy or rituximab | 21 (36) |
| Rituximab without systemic chemotherapy | 14 (24) |
| Systemic chemotherapy | 23 (40) |
| NHL protocol | 15 |
| Low-dose chemotherapeutic regimen∗ | 8 |
| With rituximab | 14 |
| Without rituximab | 9 |
| Maintenance reinitiation (data available for 58 cases) | |
| Yes | 10 (17) |
| No | 41 (71) |
| Lymphoid neoplasm diagnosed after maintenance completion | 7 (12) |
| Characteristics and treatment strategies . | Value, n (% of cases with available data) . |
|---|---|
| Histopathology | |
| Polymorphic LPD resembling polymorphic PTLD | 24 (36) |
| Monomorphic LPD | |
| B cell – DLBCL | 16 (24) |
| T cell | 2 (3) |
| Lymphomatoid granulomatosis | 15 (22) |
| EBV+ mucocutaneous ulcer | 2 (3) |
| LPD, not further specified | 7 (12) |
| Clonality (data available for 22 cases) | |
| Monoclonal | 17 (83) |
| Polyclonal | 5 (17) |
| Tumor EBV status (data available for 55 cases) | |
| Positive by IHC/ISH | 53 (96) |
| Negative | 2 (4) |
| EBV PCR in peripheral blood (copies per mL) (data available for 24 cases) | |
| Positive | 21 (88) |
| Median (range) | 40750 (17-1 500 000) |
| Negative | 3 (12) |
| Staging (data available for 60 cases) | |
| I | 4 (7) |
| II | 6 (10) |
| III | 38 (63) |
| IV | 12 (20) |
| Lymphoid neoplasm treatment strategies (data available for 58 cases) | |
| No systemic chemotherapy or rituximab | 21 (36) |
| Rituximab without systemic chemotherapy | 14 (24) |
| Systemic chemotherapy | 23 (40) |
| NHL protocol | 15 |
| Low-dose chemotherapeutic regimen∗ | 8 |
| With rituximab | 14 |
| Without rituximab | 9 |
| Maintenance reinitiation (data available for 58 cases) | |
| Yes | 10 (17) |
| No | 41 (71) |
| Lymphoid neoplasm diagnosed after maintenance completion | 7 (12) |
DLBCL, diffuse large B-cell lymphoma; IHC, immunohistochemistry; IQR, interquartile range; ISH, in-situ hybridization; PCR, polymerase chain reaction; PTLD, post-transplant lymphoproliferative disorder.
Low-dose chemotherapeutic regimen containing a cyclophosphamide/vincristine/corticosteroid as previously described.16